SCHEMBL185915

SCHEMBL185915

CC(=O)Nc1ccc(C(=O)NC2(C(=O)NCc3ccc(Nc4ccc(F)cc4C(F)(F)F)cn3)CC2)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 7/20 0.38
BCR P11274 6/20 0.38
ALDH1A1 P00352 1/20 0.37
KIT P10721 1/20 0.36
KDR P35968 1/20 0.36
MAPK14 Q16539 1/20 0.36
CNR2 P34972 1/20 0.34
BDKRB1 P46663 1/20 0.34
HDAC3 O15379 3/20 0.34
HDAC2 Q92769 3/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC6 Q9UBN7 1/20 0.34
CXCR1 P25024 1/20 0.34
CXCR2 P25025 1/20 0.34
MKNK1 Q9BUB5 3/20 0.34
MKNK2 Q9HBH9 3/20 0.34
CYP3A4 P08684 2/20 0.34
PTK2 Q05397 2/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL185570 0.92 ALDH1A1 (0.36) ALDH1A1KDRCNR2BDKRB1HDAC3
SCHEMBL14963913 0.92 HDAC3 (0.40) KITKDRMAPK14CNR2BDKRB1
SCHEMBL186050 0.90 CNR1 (0.36) ALDH1A1CNR2BDKRB1HDAC3HDAC2
SCHEMBL186730 0.89 TRPA1 (0.40) CNR2BDKRB1HDAC3HDAC2HDAC1
SCHEMBL186565 0.89 BDKRB1 (0.40) CNR2BDKRB1HDAC3HDAC2HDAC1
SCHEMBL186398 0.88 HDAC1 (0.35) ABL1BCRKITCNR2BDKRB1
SCHEMBL186387 0.88 KCNQ3 (0.42) CNR2BDKRB1HDAC3HDAC2HDAC1
SCHEMBL2811921 0.88 HDAC3 (0.38) CNR2BDKRB1HDAC3HDAC2HDAC1
SCHEMBL2807486 0.87 HDAC3 (0.41) CNR2BDKRB1HDAC3HDAC2HDAC1
SCHEMBL2804954 0.87 HDAC3 (0.44) CNR2BDKRB1HDAC3HDAC2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
EP-2401256-B1 Compounds as bradykinin B1 antagonists BOEHRINGER INGELHEIM INT (DE) 2013-04-17 EP disclosed
EP-2401256-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-01-04 EP disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131075-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 ABL1 1451/4885BCR 4614/4885ALDH1A1 1000/4885
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 ABL1 1451/4885BCR 4614/4885ALDH1A1 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.